University of Iowa Carver College of Medicine, 200 Hawkins Dr, Iowa City, IA 52242, USA.
Clin Infect Dis. 2013 Jun;56(11):1614-20. doi: 10.1093/cid/cit038. Epub 2013 Jan 29.
Rapid detection of multidrug-resistant organism (MDRO) carriers could help reduce MDRO infections by allowing for faster institution of prevention measures. However, improving the turnaround time (TAT) of a test requires attention to more than the analytic TAT, and will only occur if postanalytic processes (test reporting and care interventions) are also rapid and efficient. Obstacles to rapid MDRO test development include complex evolving resistance mechanisms, performance directly on mixed samples (eg, nares, stool), and adaptation of new methods for routine clinical diagnostic use. Existing data to support the clinical utility of rapid detection (vs standard culture methods) are scant. For these reasons, rapid detection of MDRO carriers remains a work in progress. Future efforts should be on developing rapid tests to detect multidrug-resistant gram-negative rods, particularly those harboring β-lactamases, and on performing clinical trials to determine how best to incorporate rapid detection of MDRO carriage into healthcare-associated infection prevention efforts.
快速检测多重耐药菌(MDRO)携带者有助于通过更快地采取预防措施来减少 MDRO 感染。然而,要提高检测的周转时间(TAT),不仅需要关注分析 TAT,还需要关注报告测试结果和护理干预等后分析流程的速度和效率。快速开发 MDRO 检测方法的障碍包括复杂的耐药机制、直接对混合样本(如鼻腔、粪便)进行检测以及为常规临床诊断用途而开发新方法。目前支持快速检测(与标准培养方法相比)的临床实用性的数据很少。出于这些原因,快速检测 MDRO 携带者仍然是一个正在进行的工作。未来的努力应致力于开发快速检测方法来检测耐多药革兰氏阴性杆菌,特别是那些携带β-内酰胺酶的细菌,并开展临床试验,以确定如何将 MDRO 携带的快速检测最好地纳入医疗保健相关感染预防工作中。